GlassScriptPhysician profile
Marcela J Torres
NPI 1649595646
$5,685.41
in general payments reported to CMS, 2019-2025
24 companies · $639 in 2025
The $639 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.73 · 2021: $3,573 · 2022: $304 · 2023: $738 · 2024: $418 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.89 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,028.98 | 2021 | |
| Hologic Sales and Service, LLC | $577.36 | 2021-2025 | Acessa Provu System, Aptima, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $319.38 | 2023-2025 | Veozah |
| Gynesonics, INC. | $231.77 | 2021-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Mayne Pharma Commercial LLC | $229.27 | 2023-2025 | |
| Shield Therapeutics INC | $191.55 | 2022-2024 | Accrufer |
| Abbvie INC. | $190.76 | 2021-2025 | |
| Exeltis, USA INC. | $154.12 | 2021-2025 | Slynd |
| Evofem Biosciences, INC. | $137.42 | 2024-2025 | Solosec, Phexx, Phexxi |
| Pfizer INC. | $95.12 | 2023-2024 | |
| Applied Medical Resources Corporation | $72.69 | 2021 | |
| Biogen, INC. | $71.14 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $68.47 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Sumitomo Pharma America, INC. | $67.89 | 2023-2024 | Myfembree |
| Organon LLC | $44.71 | 2024-2025 | Nexplanon |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $29.47 | 2022 | |
| Myovant Sciences INC. | $25.54 | 2022 | |
| Mission Pharmacal Company | $24.97 | 2023 | Citranatal |
| Meditrina | $23.42 | 2022 | |
| Becton, Dickinson and Company | $22.92 | 2024 | Bd Onclarity |
| Scynexis, INC. | $22.14 | 2022 | |
| Millicent US INC | $21.40 | 2024 | Intrarosa, Femring |
| Therapeuticsmd, INC. | $21.19 | 2022 | |
| Duchesnay USA Incorporated | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcela Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.